Few cases of GCA secondary to the introduction of ICI (anti PD-1/PD-L1, anti CTLA-4) therapy have been reported even though PD-1/PD-L1 pathway dysfunction has been demonstrated during GCA [55]. The gene discussed is CTLA4; the disease is temporal arteritis.